RAVENSBURG, Germany--(Vetter has announced that it has now been approved as a “Known Consignor” by the German Federal Aviation Office. The agency officially granted the pharmaceutical service provider the certificate of approval following an audit at Vetter´s Holbeinstrasse and Ravensburg Vetter West facilities. The approval means that customers will continue to have their air cargo products loaded, transported and delivered quickly and safely, saving valuable time and money.)--
“Once time-consuming x-rays and searches are no longer necessary, saving invaluable effort and cost. For Vetter, the status of”
Vetter had already been designated as a “Known Consignor” back in 2006. The goal of the certification is primarily to provide more security for air cargo. Until recently, logistics companies themselves issued the certificate. New EU regulations concerning the so-called "safe supply chains" require that companies must now have their status audited and approved by the Federal Aviation Office. The criteria for certification are extensive and include elaborating a safety concept, training personnel, and the assurance that the shipping of freight is performed in a way that cannot be tampered with. Any attempt to open the shipment would be immediately evident. The Federal Aviation Office grants the certificate for five years and carries out unannounced controls on a regular basis.
"Our approval as a "Known Consignor" allows our customers fast and smooth loading of air freight packages at the airport, including a high level of security,” said managing director Thomas Otto. “Once time-consuming x-rays and searches are no longer necessary, saving invaluable effort and cost. For Vetter, the status of ”Known Consignor” is further proof of the high product quality that we offer our customers.”
Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons and vaccines. Its clientele includes the world’s top 10 pharma/biotech firms and emerging companies alike. A full-service provider, Vetter supports products throughout their lifecycles, from preclinical development through global market supply. Through its U.S. and European facilities, Vetter Development Service provides state-of-the-art support for early-stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. The company is the originator of dual-chamber technology, which enables easier, safer lyophilized-drug administration; and is a leader in the use of RABS technology in cleanrooms, which mitigates risk of product contamination during the manufacturing process. Vetter has won numerous awards for innovation and quality, including top prize at the 2012 European Outsourcing Awards for its new high-speed filling line. Headquartered in Ravensburg, Germany, the company employs approximately 3,000 staff across Europe and the United States. For more information about Vetter, visit www.vetter-pharma.com